Both the human monoclonal antibody canakinumab targeting IL-1β and the dimeric fusion protein rilonacept that neutralizes IL-1β are extremely effective and have FDA approval for CAPS treatment [17]. Here, IL1B is linked to cryopyrin-associated periodic syndrome.